Viking Therapeutics (XTER:1VT) Cyclically Adjusted PB Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:1VT Viking Therapeutics Inc XTER:1VT
34 GF Score
Price €28.30
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viking Therapeutics  (XTER:1VT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Viking Therapeutics Cyclically Adjusted PB Ratio Related Terms


Viking Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Cyclically Adjusted PB Ratio Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 5.09 8.70 12.83 9.13

Viking Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.33 7.00 9.13 8.11 9.46

XTER:1VT vs : Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Viking Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Cyclically Adjusted PB Ratio falls into.


XTER:1VT
34GF Score
Viking Therapeutics Inc XTER:1VT
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Viking Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Viking Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.5/333.9520*333.9520
=3.500

Current CPI (Jun. 2026) = 333.9520.

Viking Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.514 241.428 0.711
201612 0.386 241.432 0.534
201703 0.315 243.801 0.431
201706 0.238 244.955 0.324
201709 0.078 246.819 0.106
201712 0.376 246.524 0.509
201803 1.426 249.554 1.908
201806 2.314 251.989 3.067
201809 4.237 252.439 5.605
201812 4.150 251.233 5.516
201903 4.090 254.202 5.373
201906 3.995 256.143 5.209
201909 3.923 256.759 5.102
201912 3.827 256.974 4.973
202003 3.697 258.115 4.783
202006 3.600 257.797 4.663
202009 3.480 260.280 4.465
202012 3.337 260.474 4.278
202103 3.074 264.877 3.876
202106 2.877 271.696 3.536
202109 2.724 274.310 3.316
202112 2.580 278.802 3.090
202203 2.356 287.504 2.737
202206 2.155 296.311 2.429
202209 1.973 296.808 2.220
202212 1.857 296.797 2.089
202303 1.690 301.836 1.870
202306 3.860 305.109 4.225
202309 3.681 307.789 3.994
202312 3.480 306.746 3.789
202403 8.472 312.332 9.058
202406 8.312 314.175 8.835
202409 8.179 315.301 8.663
202412 7.890 315.605 8.349
202503 7.542 319.799 7.876
202506 7.081 322.561 7.331
202509 6.341 324.800 6.520
202512 5.567 324.054 5.737
202603 4.331 330.213 4.380
202606 3.500 333.952 3.500

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viking Therapeutics Business Description

Comparable Companies
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
34GF Score

Get the complete analysis for XTER:1VT

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.30
Price